m-lab GmbH is a spin-off from the University of Mainz, Germany. We are developing and commercializing innovative point-of-care (POC) devices and personalized treatment approaches in Ophthalmology.

The initial product, a Glaucoma diagnostic platform, will provide early detection of Glaucoma, the most prevalent cause of blindness in the world today, by means of an affordable, easy-to-use, point-of-care test, yielding a Glaucoma Risk Score within a few minutes independent from specialized laboratories. We foresee a yearly test at below €20 for all people aged over 50 years.

The test is based on m-lab’s innovative highly sensitive multiplexing lateral flow platform detecting disease specific marker patterns in tear fluid with a reader and combined smartphone reader software for A.I. based disease scoring.

After final prototype optimization and licencing of the Glaucoma test system, we expect the launch the diagnostic platform within the next 2 years.
In parallel, we are continuously developing our therapeutic antibody program, with the aim of developing urgently needed new neuroprotective treatment options to prevent blindness.
We are now looking for the next financial round (e.g. VC and M+A) for the next 2 years, strategic partners and licensing options.

We would be happy to discuss various options for business cooperation at a meeting.

If you are beside of glaucoma interested in:

• using the m-lab proprietary technology for multiplexing lateral flow assays adaptable to different samples (e.g. blood, tears, saliva etc.) and targets (DNA/RNA, proteins, antibodies)

• LFT for monitoring covid vaccination protection (on the market
  in Japan)

• OEM manufacturing of LFT

• Developing and consulting in diagnostic developments

• Contract manufacturing/ contract development/ 3rd party production

• Licensing and distribution

• Diagnostic and therapeutic developments in other eye diseases
  like AMD

Please contact us for more details.

News

• m-lab was granted the patents in all large market countries like USA, China, Europe, Japan, etc.

• m-lab reaches sensitivity and specificity of > 90% in glaucoma detection

• m-lab could successfully validate the working test prototype

• m-lab could show extraordinary therapeutic effect of antibody treatment in glaucoma animal model and eye explants

• m-lab offers unique lateral flow platform technology

We are currently looking for financial support (e.g. VC and M+A) for the 2 years, strategic partners and licensing options.

Company objectives

• Seeking investors to support final development, licensing and market launch for our diagnostic and risk of progression test for Glaucoma

• Development of novel personalized antibody-based treatment, based on the patient’s diagnostic profile.

• Seeking new opportunities for co-development and out-lincensing.